and prurigo nodularis (firm bumps). Studies show people of color in the United States are more likely to develop atopic dermatitis and experience more severe symptoms compared to white people.

Nemolizumab “is also the first and only biologic approved for atopic dermatitis and prurigo nodularis with 4-week dosing intervals from the start of treatment,” according to the statement.

If you have a darker skin tone, you might see small, hardened, very itchy bumps, known as prurigo nodularis, on areas of your skin affected by atopic dermatitis. You may also be likely to get ...

showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis 1-3 There is a need for new treatment options for atopic ...

long-term therapeutic option for patients with atopic dermatitis and prurigo nodularis seeking relief from itch and skin lesions. We remain steadfast in our efforts to bring this potential ...

SILVERBERG: Atopic dermatitis is a complex and heterogeneous ... the potential involvement of IL-31 in conditions like prurigo nodularis with emerging considerations for disorders such as ...

Ruxolitinib cream is effective for atopic dermatitis and prurigo nodularis, with low adverse event rates in long-term use. The cream reduces the need for other topical treatments and biologics in ...

Vakharia is assistant professor of dermatology at Northwestern University Feinberg School of Medicine in Chicago. The information here represents his knowledge and experience as a medical ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

22,23 “The robust evidence base we have built for nemolizumab in both atopic dermatitis and prurigo nodularis shows the extent of its potential in improving outcomes for these diseases where the ...

9 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis.